Dr Richard Hoglund
Head of Pharmacometrics
Richard Hoglund heads the pharmacometrics group at the department of Clinical Pharmacology, MORU. He has a background in chemical engineering and pharmacology and his research is mainly focused on pharmacometrics, pharmacokinetics, pharmacodynamics and mathematical modelling in tropical medicine research, with a particular focus on antimalarial therapy.
More specific, his main research aims to optimise current and future antimalarial therapies by utilizing pharmacometric methodologies. A pharmacometric modelling approach can identify specific groups at risk of treatment failure and the derived pharmacometric models can help to evaluate and suggest new dose regimens to improve the treatment of malaria.
Concentration-dependent mortality of chloroquine in overdose
Watson JA. et al, (2020), eLife, 9
Safety, Pharmacokinetics, and Mosquito-Lethal Effects of Ivermectin in Combination With Dihydroartemisinin-Piperaquine and Primaquine in Healthy Adult Thai Subjects.
Kobylinski KC. et al, (2020), Clinical pharmacology and therapeutics, 107, 1221 - 1230
An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.
Francis J. et al, (2020), Antimicrobial agents and chemotherapy, 64
Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers
von Seidlein L. et al, (2020), Human Vaccines & Immunotherapeutics, 16, 33 - 41
A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa
Onyamboko MA. et al, (2019), Antimicrobial Agents and Chemotherapy, 64